Abiomed (ABMD) Misses Q2 EPS by 4c; Maintains Revenue Outlook

Abiomed (NASDAQ: ABMD) reported Q2 EPS of $0.20, $0.04 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $103 million versus the consensus estimate of $103.16 million.

GUIDANCE:

Abiomed maintains FY2017 revenue of $435-445 million, versus the consensus of $446.33 million.

For earnings history and earnings-related data on Abiomed (ABMD) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79